Phase 2 N=142 Efficacy of Antidepressants in Chronic Back Pain
Back Pain
Primary: Intent-toTreat Analysis of Descriptor Differential Scale (DDS) of Pain Intensity — 8.3; 8.1 units on a scale — p=0.7
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=88 Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
NSCLC
Primary: Objective Response Rate (ORR) in Each Study Arm Based on Independent Central Radiology Review — 0; 0; 15; 6 participants — p=0.2895
Phase 1 N=136 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 21; 3; 3; 5 participants
Phase 2 N=51 LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Malignant Glioma
Primary: LBH589 Maximum Tolerated Dose (MTD) [Phase I] — 30 mg/day orally, 3x per wk, every other wk
N/A N=34 Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Diabetes Type 2
Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67
Phase 2 N=110 Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Arbitrary Accelerometry Units (AAU) (Phase I) — 9370; 9538 accelerometry units
Phase 3 N=647 Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (or Early Termination) — -0.32; -1.23; -1.06; -1.72 percentage of glycosylated hemoglobin — p=< 0.0001
Phase 4 N=300 Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season
Influenza · Healthy
Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0; 0.4 Percentage of Participant
Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Phase 2 N=10 Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue or Post-neutral - Via the Visual Analog Scale for Craving (VASC) — 2.67; 0.83; -0.33; -0.17 units on…
Phase 3 N=11 A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 100; 18.2 Percentage of participants
Phase 3 N=62 Improving the Understanding of the Response to Vitamin D Supplementation
Vitamin D Deficiency
Primary: Change in Serum 25-hydroxy Vitamin D3 — 6.0; -0.8; 10.4; 0.3 ng/ml
Phase 4 N=39 Wound Fluid Protease Levels During Use of Novel Wound Dressing
Venous Stasis Ulcers
Primary: Matrix Metalloproteinase Level in Wound Fluid — 0.71; 0.88 mcg/ml
Phase 4 N=17 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression
Major Depression · Irritable Bowel Syndrome
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 31.59; 15.67; 11.4 units on a scale — p=<.05
Phase 3 N=165 Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)
Peripheral Spondyloarthritis
Primary: Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12 — 39.3; 19.8; 60.7; 80.2 percentage of participants — p=0.006